Seasonal influenza virus vaccine inactivated split-trivalent (GlaxoSmithKline)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameSeasonal influenza virus vaccine inactivated split-trivalent (GlaxoSmithKline)

Drug Alias NameNew generation flu vaccine inactivated split (trivalent, GlaxoSmithKline)季节性三价灭活病毒疫苗（葛兰素史克）New generation flu vaccine (inactivated split trivalent, GlaxoSmithKline)GSK-2186877A

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Inactivated vaccine > Split vaccineVaccines > Biological material > Viral vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsInfluenza, Human

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumCanada +[18]

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc

Active IndicationsN/A

Inactive IndicationsInfluenza, Human

Other Information

ATC CodeN/A